|  |  |  |
| --- | --- | --- |
|  | **Seminoma** | **Nonseminoma** |
|  | **Relapse group** | **Relapse group** |
| **Relapse characteristics** | **ER** | **LR(+VLR)** |  | **ER** | **LR(+VLR)** |  |
| **Number pt.** | 288 | 100 |  | 400 | 24 |  |
| **Age at relapse, yrs, median (IQR)** | 38(32-45) | 39(34-49) |  | 29(25-37) | 39(31-47) |  |
| **Time of relapse****Year 0****Year 1****Year 2****Year 3****Year 4****After 5 years** | 169119---- | --45211717 |  | 33862---- | --8574 |  |
| **hCG elevation****Yes (%)****No (%)** | 33 (11)255 (89) | 16 (16)84 (84) |  | 170 (43)230 (57) | 2 (8)22(92) |  |
| **AFP elevation****Yes (%)****No (%)** | 4 (1)284 (99) | 4 (4)96 (96) |  | 178 (44)222 (56) | 6 (25)18 (75) |  |
| **Relapse biopsy, number****Seminoma (%)****Nonseminoma (%)****-teratoma****N/A** | 191177(93)6 (3)18 (4) | 8778 (90)5 (6)14 (4) |  | 1338(6)106(80)1419 (14) | 155(33)10(67)10 (0) |  |
| **Relapse stage\*****IIa (%)****IIb (%)****IIc (%)****IIIa (%)****IIIb (%)****IS (%)****N/A (%)** | 102 (35)118 (41)47 (16)6 (2)7 (2)7 (2)1 (0) | 24 (24)35 (35)32 (32)6 (6)3 (3)0 (0)0 (0) |  | 117 (29)92 (23)24 (6)10 (3)69 (17)68 (17)20 (5) | 3 (13)7 (29)7 (29)0 (0)6 (25)1(4)0 (0) |  |
| **Treatment****RT (%)****BEP (%)****Surgery only (%)** | 198 (69)88 (31)2 (1) | 42 (42)57 (57)1 (1) |  | 4 (1)386 (97)8 (2) | 0 (0)21 (87)3 (13) |  |
| **Posttreatment surgery(%)****-teratoma** | 11 (4)1 | 14 (14)2 |  | 91 (23)59 | 8 (33)1 |  |
| **Death of TC:****-Progressive disease****-Complications \*\*** | 4 3 | 32 |  | 9 5  | 01 |  |
| **5 year DSS %** | 98.2 | 94.9 |  | 97.0 | 98.2 |  |
| **5 year OS %** | 95.8 | 93.8 |  | 95.2 | 95.8 |  |

Table 2. Patient characteristics at time of relapse.

Patients are grouped according to their primary histology. Abbreviations ER: early relapse, LR(+VLR): late and very late relapses, pt: patients, yrs: years, IQR: inter quartile range, AFP: alpha fetoprotein, hCG: human chorionic gonadotropin, RT: radiotherapy, BEP: bleomycin, etoposide, cisplatin, TC: testicular cancer, DSS: disease specific survival, OS: overall survival. \* See supplemental table 3 for definition of stages \*\* death from complications were due to kidney failure, pulmonary embolism, pulmonary edema, septicemia (4 patients), pneumonia (2 patients),and bleomycin induced pneumonitis (2 patients).